Rafferty Asset Management LLC decreased its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 5.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 32,793 shares of the company’s stock after selling 2,027 shares during the quarter. Rafferty Asset Management LLC owned approximately 0.09% of Stoke Therapeutics worth $1,104,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Millennium Management LLC acquired a new stake in Stoke Therapeutics during the first quarter valued at approximately $3,087,000. Geode Capital Management LLC grew its holdings in shares of Stoke Therapeutics by 8.1% during the first quarter. Geode Capital Management LLC now owns 293,036 shares of the company’s stock valued at $11,381,000 after purchasing an additional 21,871 shares during the last quarter. Sphera Funds Management LTD. bought a new position in shares of Stoke Therapeutics during the first quarter valued at approximately $5,854,000. Alliancebernstein L.P. grew its holdings in shares of Stoke Therapeutics by 9.4% during the second quarter. Alliancebernstein L.P. now owns 19,800 shares of the company’s stock valued at $666,000 after purchasing an additional 1,700 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Stoke Therapeutics during the first quarter valued at approximately $416,000. Institutional investors and hedge funds own 55.00% of the company’s stock.
In other news, insider Barry Ticho sold 43,166 shares of the company’s stock in a transaction on Tuesday, July 13th. The shares were sold at an average price of $32.75, for a total value of $1,413,686.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Huw M. Nash sold 5,700 shares of the company’s stock in a transaction on Wednesday, September 1st. The stock was sold at an average price of $26.00, for a total transaction of $148,200.00. Following the completion of the transaction, the chief operating officer now directly owns 5,700 shares in the company, valued at $148,200. The disclosure for this sale can be found here. Insiders sold 54,566 shares of company stock valued at $1,726,446 in the last 90 days. Corporate insiders own 51.80% of the company’s stock.
Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Tuesday, August 10th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.14). As a group, research analysts expect that Stoke Therapeutics, Inc. will post -2.25 earnings per share for the current fiscal year.
Several equities analysts have recently commented on STOK shares. Zacks Investment Research raised Stoke Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 22nd. Cantor Fitzgerald cut their target price on Stoke Therapeutics from $76.00 to $68.00 and set an “overweight” rating for the company in a research report on Tuesday, August 17th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $63.63.
Stoke Therapeutics Company Profile
Stoke Therapeutics, Inc is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
Featured Story: What does RSI mean?
Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. (NASDAQ:STOK).
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.